Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
124,693,841
-
Share change
-
+10,894,568
-
Total reported value
-
$278,605,461
-
Put/Call ratio
-
343%
-
Price per share
-
$2.23
-
Number of holders
-
127
-
Value change
-
+$21,793,021
-
Number of buys
-
44
-
Number of sells
-
75
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q1 2025
As of 31 Mar 2025,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
124,693,841 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC, Capital World Investors, BAILLIE GIFFORD & CO, Voya Investment Management LLC, UBS Group AG, ORBIMED ADVISORS LLC, ArrowMark Colorado Holdings LLC, BlackRock, Inc., and TWO SIGMA INVESTMENTS, LP.
This page lists
128
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.